Advanced Therapies Conference to Include Gene Modified Therapy Track – Exacis Biotherapeutics CEO to Participate in Panel Discussion

On May 7, 2022 Dr. Gregory Fiore, Co-Founder, President and CEO of Exacis Biotherapeutics reported that it will serve on a panel exploring the difference between autologous and allogeneic stem cell therapies during the Advanced Therapies Conference (Press release, Exacis Biotherapeutics, MAY 7, 2022, View Source [SID1234613846]). The panel, "Autologous vs Allogeneic," is part of the Gene Modified Cell Therapy track for conference attendees. Exacis is a cell therapy company using mRNA to reprogram somatic cells to iPSCs and then using a proprietary mRNA based gene editing platform to engineer the cells before differentiation into immune effector (T and NK) cells for cancer applications. Dr. Fiore will share his knowledge of the research and developments in the rapidly growing cell therapy field.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The currently approved autologous cell therapies are making a big difference for patients, although they are limited in their availability due to multiple factors. Allogeneic therapies hold promise to overcome these accessibility barriers," said Dr. Fiore. "Exacis and others are working to develop lower cost, off-the-shelf cell therapies in order to allow many more patients to benefit from these lifesaving treatments."

The panel will take place at 12:20 pm GMT on Wednesday, May 25.

The Advanced Therapies Conference will be held May 24-25, 2022, in London. Meeting attendees will explore important topics in the Advanced Therapy Medicinal Products (ATMP) space and the conference will showcase the latest technologies and advancements in the industry. The event will bring together 1,500 attendees from across the ATMP industry from pharma, biotech, research, regulatory bodies, HTAs investment and start-ups. The agenda includes 8 focused topic tracks, 300 speakers, and 100 sponsors and exhibitors.